Protagonist Therapeutics, Inc.
US ˙ NasdaqGM ˙ US74366E1029

SecurityPTGX / Protagonist Therapeutics, Inc.
InstitutionFmr Llc
Latest Disclosed Ownership385,863 shares
Ownership 0.78%
Fmr Llc ownership in PTGX / Protagonist Therapeutics, Inc.

2022-12-12 - Fmr Llc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 385,863 shares of Protagonist Therapeutics, Inc. (US:PTGX). This represents 0.784 percent ownership of the company. In their previous filing dated 2022-06-10 , Fmr Llc had reported owning 3,554,095 shares, indicating a decrease of -89.14 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2022-12-12 2022-12-12 13G/A 3,554,095 385,863 -89.14 0.78 -89.27
2022-06-10 2022-06-10 13G/A 6,847,277 3,554,095 -48.09 7.30 -49.09
2022-02-09 2022-02-09 13G/A 6,452,764 6,847,277 6.11 14.35 -4.86
2021-02-08 2021-02-08 13G/A 4,080,967 6,452,764 58.12 15.08 0.53
2020-02-07 2020-02-07 13G/A 3,627,902 4,080,967 12.49 15.00 0.00
2019-02-13 2019-02-13 13G/A 3,071,949 3,627,902 18.10 15.00 0.00
2018-02-13 2018-02-13 13G/A 2,507,167 3,071,949 22.53 15.00 0.00
2017-02-14 2017-02-14 13G/A 2,128,719 2,507,167 17.78 15.00 15.99
2016-10-11 2016-10-11 13G 2,128,719 12.93

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 661,997 122,119 22.62 69,774 47.98 0.0007
2026-02-17 2025-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 539,878 19,214 3.69 47,153 36.33 0.0024
2025-11-13 2025-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 520,664 -17,768 -3.30 34,588 16.22 0.0018
2025-08-14 2025-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 538,432 60,089 12.56 29,759 28.65 0.0017
2025-05-12 2025-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 478,343 35,827 8.10 23,133 35.43 0.0015
2025-02-13 2024-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 442,516 -11,680 -2.57 17,081 -16.43 0.0010
2024-11-13 2024-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 454,196 19,737 4.54 20,439 35.76 0.0012
2024-08-13 2024-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 434,459 -31,626 -6.79 15,054 11.65 0.0010
2024-05-13 2024-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 466,085 133 0.03 13,484 26.20 0.0009
2024-02-13 2023-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 465,952 -43,290 -8.50 10,684 25.78 0.0008
2023-11-13 2023-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 509,242 1,835 0.36 8,494 -39.39 0.0007
2023-08-11 2023-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 507,407 459,087 950.10 14,015 1,161.39 0.0012
2023-08-11 2023-03-31 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 48,320 -20,206 -29.49 1,111 48.73 0.0001
2023-05-11 2023-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 48,320 -20,206 1,111 0.0001
2023-02-13 2022-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 68,526 -2,740,282 -97.56 748 -96.85 0.0001
2022-11-10 2022-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 2,808,808 -682,198 -19.54 23,679 -14.25 0.0025
2022-08-12 2022-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 3,491,006 -3,637,573 -51.03 27,613 -83.64 0.0028
2022-05-13 2022-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 7,128,579 281,302 4.11 168,805 -27.92 0.0135
2022-02-14 2021-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 6,847,277 354,639 5.46 234,177 103.55 0.0173
2022-02-14 2021-09-30 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 6,492,638 -623,745 -8.76 115,049 -63.98 0.0091
2021-11-15 2021-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 6,492,638 -623,745 115,049 0.0091
2021-08-13 2021-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 7,116,383 545,156 8.30 319,383 87.66 0.0250
2021-05-14 2021-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 6,571,227 118,463 1.84 170,195 30.83 0.0145
2021-02-08 2020-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 6,452,764 1,251,683 24.07 130,087 27.94 0.0116
2020-11-13 2020-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 5,201,081 35,876 0.69 101,682 11.47 0.0103
2020-08-24 2020-06-30 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 5,165,205 1,071,061 26.16 91,217 215.58 0.0100
2020-08-13 2020-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 5,165,205 1,071,061 91,217 2,240.9348
2020-05-14 2020-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 4,094,144 13,177 0.32 28,905 0.47 0.0040
2020-02-07 2019-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 4,080,967 138,955 3.52 28,771 -39.23 0.0032
2019-11-13 2019-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 3,942,012 432,608 12.33 47,344 11.40 0.0057
2019-08-13 2019-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 3,509,404 -97,845 -2.71 42,499 -6.27 0.0050
2019-05-13 2019-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 3,607,249 -20,653 -0.57 45,343 85.71 0.0054
2019-02-13 2018-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 3,627,902 170,500 4.93 24,416 -31.37 0.0033
2018-11-09 2018-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 3,457,402 276,819 8.70 35,577 66.45 0.0040
2018-08-10 2018-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 3,180,583 15,017 0.47 21,374 -21.40 0.0025
2018-05-14 2018-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 3,165,566 93,617 3.05 27,192 -57.44 0.0032
2018-02-12 2017-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 3,071,949 536,535 21.16 63,897 42.62 0.0075
2017-11-13 2017-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 2,535,414 6,952 0.27 44,801 56.66 0.0054
2017-08-29 2017-06-30 13F/A-1 PROTAGONIST THERAPEUTICS COM 74366E102 2,528,462 10,264 0.41 28,597 -11.35 0.0036
2017-08-11 2017-06-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 2,528,462 10,264 28,597
2017-05-11 2017-03-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 2,518,198 11,031 0.44 32,258 -41.49 0.0041
2017-02-10 2016-12-31 13F PROTAGONIST THERAPEUTICS COM 74366E102 2,507,167 378,448 17.78 55,133 22.57 0.0074
2016-11-14 2016-09-30 13F PROTAGONIST THERAPEUTICS COM 74366E102 2,128,719 2,128,719 44,980 0.0060
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.